[Cyclical chemotherapy of myeloma with cell synchronization: therapeutic trial. Apropos of 13 cases].
The authors report the results obtained from the treatment of 13 cases of myeloma by cyclic chemotherapy (melphalan) applied after cellular synchronization with vincristine. The clinical results (maximum 2 years after treatment) were good in 11 cases out of 13. The following laboratory values quickly returned to normal: sedimentation and calcaemia, but there was little change in the immunoglobulins.
D000368:Aged; D000740:Anemia / Q000628:therapy; D001799:Blood Sedimentation; D001859:Bone Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006934:Hypercalcemia / Q000628:therapy; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D008938:Mitosis; D009101:Multiple Myeloma / Q000188:drug therapy*; D010146:Pain; D010507:Periodicity; D014750:Vincristine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
D014750:Vincristine; D008558:Melphalan
Chimiothérapie cyclique du myélome avec synchronisation cellulaire: essai thérapeutique. A propos de 13 observations